Cullinan Oncology LLC (CGEM)

NASDAQ
Currency in USD
9.53
-0.06(-0.63%)
Closed
After Hours
9.530.00(0.00%)
CGEM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
Fair Value
Day's Range
9.479.93
52 wk Range
9.4730.19
Key Statistics
Edit
Prev. Close
9.59
Open
9.58
Day's Range
9.47-9.93
52 wk Range
9.47-30.19
Volume
280.82K
Average Volume (3m)
524.19K
1-Year Change
-47.72%
Book Value / Share
10.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CGEM Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
33.89
Upside
+255.60%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Cullinan Oncology LLC Company Profile

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company’s development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Compare CGEM to Peers and Sector

Metrics to compare
CGEM
Peers
Sector
Relationship
P/E Ratio
−3.9x−3.5x−0.7x
PEG Ratio
−0.180.040.00
Price/Book
0.9x2.0x2.6x
Price / LTM Sales
-27.8x3.1x
Upside (Analyst Target)
246.3%212.2%47.6%
Fair Value Upside
Unlock5.8%7.7%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 33.89
(+255.60% Upside)

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
-0.69 / -0.7879
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

25.39
EWTX
-2.42%
36.88
KYMR
+0.68%
2.130
SLRN
+3.40%
8.28
KURA
0.00%

FAQ

What Is the Cullinan Oncology LLC (CGEM) Stock Price Today?

The Cullinan Oncology LLC stock price today is 9.53

What Stock Exchange Does Cullinan Oncology LLC Trade On?

Cullinan Oncology LLC is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Cullinan Oncology LLC?

The stock symbol for Cullinan Oncology LLC is "CGEM."

What Is the Cullinan Oncology LLC Market Cap?

As of today, Cullinan Oncology LLC market cap is 554.91M.

What is Cullinan Oncology LLC Earnings Per Share?

The Cullinan Oncology LLC EPS is -2.88.

What Is the Next Cullinan Oncology LLC Earnings Date?

Cullinan Oncology LLC will release its next earnings report on 06 Mar 2025.

From a Technical Analysis Perspective, Is CGEM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.